Investor Relations
And information
HomeInvestor Relations› Tornier Announces Launch of BioFiber® Surgical Mesh for Tendon Repair at Arthroscopic Surgery Conference
News Releases
View printer-friendly version << Back
Tornier Announces Launch of BioFiber® Surgical Mesh for Tendon Repair at Arthroscopic Surgery Conference

April 14, 2011

BioFiber Expands Tornier Portfolio of Innovative Products for the Repair of Rotator Cuff and Other Tendon Injuries

Tornier (NASDAQ: TRNX), a global leader in extremity orthopaedics, today announced the launch of its BioFiber® Surgical Mesh for the repair of rotator cuff and other tendon injuries at the 30th Annual Meeting of the Arthroscopic Association of North America Meeting (AANA) held in San Francisco. Utilized to treat over 100 patients since its limited commercial release in December 2010, the BioFiber Surgical Mesh complements Tornier’s expanding line of biologic products for upper and lower extremity surgeons, including the Conexa™ Reconstructive Tissue Matrix that has been in clinical use since 2008.

John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at the Mayo Clinic in Rochester, Minnesota, commented, “Surgery for the re-attachment of tendons or ligaments to bone, such as a rotator cuff repair, can be associated with a later re-tear at the attachment site, especially in patients with compromised healing function. BioFiber’s unique mesh design and its biocompatible resorbable polymer composition provide an ideal scaffold to support healing at these surgical attachment sites. Combined with its ease of use and cost effectiveness, I have found the BioFiber Surgical Mesh to be a useful product in my practice to reinforce attachment sites during tendon and ligament surgeries.”

Under development by Tornier for over three years, BioFiber Surgical Mesh is distinguished by both its mesh design and polymer composition. The mesh is a proprietary three dimensional structure designed to provide a strong, but flexible scaffold for cell migration and enhanced healing. The fibers of the mesh are derived from a new class of proprietary resorbable polymers called polyhydroxyalkanoates (PHAs). Developed by Tornier’s corporate partner, Tepha Medical Devices of Lexington, Massachusetts, the PHA family of resorbable polymers is characterized by a unique profile of strength, flexibility, and tissue compatibility that is ideal for a broad range of implantable medical devices.

About Tornier

Tornier N.V. is a global medical device company focused on serving extremities specialists that treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The company’s broad offering of over 70 product lines includes joint replacement, trauma, sports medicine, and orthobiologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier’s “Specialists Serving Specialists” philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit

Safe Harbor Statement

This Press Release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this Press Release include the intent, belief or current expectations of the Company and members of its management team with respect to the Company’s future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, the Company’s ability to successfully integrate, achieve and capitalize on its new products. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can also be found in the Company’s Risk Factor disclosures in its Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on June 8, 2010. The Company disclaims any responsibility to update any forward-looking statements.

Tornier Corporate Communications
Kirsten Harrison, +1-952-426-7600

Source: Tornier 

News Provided by Acquire Media